CRISPR has moved well beyond the lab. Since its development as a gene-editing tool in 2012, it has been used to treat blood disorders, fight cancer, grow hardier crops, engineer animal organs for human transplant, diagnose infections, and even modify mosquitoes to combat malaria. The first CRISPR-based therapy received FDA approval in December 2023, and applications across medicine, agriculture, and industry continue to expand.
Treating Sickle Cell Disease
The highest-profile use of CRISPR so far is Casgevy, the first gene-editing therapy approved by the FDA, cleared on December 8, 2023 for sickle cell disease. The treatment works by removing a patient’s blood stem cells, using CRISPR to edit them so they produce fetal hemoglobin (a form of hemoglobin that prevents red blood cells from sickling), and then transplanting those edited cells back into the patient’s bone marrow.
In clinical trials, 29 out of 31 evaluable patients (93.5%) were free from severe pain crises for at least 12 consecutive months after treatment. That’s a striking result for a disease that causes repeated, debilitating episodes of pain and organ damage throughout a person’s life. As of late 2025, Casgevy remains one of only a small number of gene therapies on the FDA’s approved list.
Restoring Vision in Inherited Blindness
One of CRISPR’s most remarkable applications targets a rare form of genetic blindness called Leber Congenital Amaurosis Type 10. An experimental treatment called EDIT-101 uses CRISPR to fix the mutation directly inside the eye, making it one of the first times CRISPR has been used to edit genes inside the human body rather than in cells removed and returned.
Results from the BRILLIANCE trial, published in the New England Journal of Medicine, showed that about 79% of the 14 participants experienced measurable improvements in vision. Eleven of those 14 people saw gains in both vision and quality of life. The trial included 12 adults and two children, and no approved treatment previously existed for this condition.
Engineering Stronger Cancer-Fighting Cells
CRISPR is being used to supercharge a type of cancer treatment called CAR-T cell therapy, where a patient’s own immune cells are extracted, reprogrammed to recognize cancer, and infused back into the body. CAR-T therapies targeting specific markers on cancer cells are already approved for B-cell leukemias and multiple myeloma. CRISPR adds a new layer: editing those immune cells to make them more effective and longer-lasting.
One major problem with CAR-T cells is that they become “exhausted” inside the body, losing their ability to attack tumors over time. CRISPR lets researchers knock out the genes responsible for that exhaustion. For example, disabling a protein called PD-1 in engineered immune cells has shown enhanced tumor-killing ability in glioblastoma, breast cancer, and liver cancer models. Researchers have also used CRISPR to delete genes that make immune cells vulnerable to the suppressive chemical signals tumors produce, essentially making the cells resistant to the tumor’s defenses.
Clinical trials are now underway using CRISPR-edited immune cells against solid tumors including breast cancer, glioblastoma, lung cancer, prostate cancer, and gastrointestinal cancers. These are cancers where standard CAR-T therapy has historically struggled.
Pig Organs for Human Transplant
The global shortage of donor organs has pushed researchers toward xenotransplantation, transplanting organs from pigs into humans. The challenge is that the human immune system immediately attacks pig tissue. CRISPR has made it possible to edit pig genomes at an unprecedented scale, knocking out the genes that trigger immune rejection and adding human genes that help the organ survive.
Some pigs have been modified at 10 or more gene targets in a single animal, removing molecules that provoke immune attack, inactivating pig viruses embedded in the genome, and inserting human proteins that regulate blood clotting and inflammation. In 2022, a patient named David Bennett Sr. received a heart from a heavily gene-edited pig. The heart functioned for about two months before eventually failing. That same year, researchers at the University of Alabama transplanted a kidney from a 10-gene-modified pig into a brain-dead recipient to study how the organ performed.
These early cases are proof-of-concept rather than routine medicine, but they represent a use of CRISPR that could eventually address the tens of thousands of people waiting for organ transplants.
Faster, More Sensitive Disease Diagnostics
CRISPR isn’t only used to edit genes. Platforms called SHERLOCK and DETECTR repurpose CRISPR’s ability to find specific genetic sequences, turning it into a diagnostic tool. When the CRISPR protein finds its target (say, a snippet of viral RNA), it triggers a signal that can be read on a simple test strip, similar in concept to a pregnancy test.
The sensitivity is dramatically better than standard lab tests. CRISPR-based diagnostics can detect targets at the attomolar level, picking up SARS-CoV-2 RNA at just 4 copies per microliter. Standard PCR tests, by comparison, work at sensitivity levels roughly a thousand times less precise. CRISPR diagnostics can also differentiate between closely related pathogen subtypes with 100% accuracy, as demonstrated with different species of the fungus Cryptococcus.
Speed is the other advantage. A CRISPR diagnostic test takes 30 minutes to an hour, while a standard PCR test requires 2 to 4 hours because of its thermal cycling process. Microfluidic chip versions of CRISPR tests have pushed that time below 30 minutes, making them viable for emergency rooms and field settings in ways that PCR never could be.
Editing Crops for Better Yields and Nutrition
In agriculture, CRISPR is being used to develop crops that are more nutritious, more resilient, or easier to process. Unlike older genetic modification techniques that insert foreign DNA, CRISPR often makes small, targeted changes to a plant’s own genome, which has led several countries to regulate these crops differently from traditional GMOs.
Current projects span a wide range. In Peru, researchers are using CRISPR to reduce cadmium absorption in cocoa plants, addressing a significant food safety concern since cadmium is a toxic heavy metal that accumulates in chocolate. Potato varieties are being edited for increased tolerance to disease and environmental stress. Lupins and quinoa are being modified to lower their naturally occurring bitter or toxic compounds (alkaloids and saponins), which currently require extensive processing to remove. Tomato research has focused on identifying and editing genes linked to disease susceptibility.
Suppressing Malaria-Carrying Mosquitoes
CRISPR gene drives represent one of the most ambitious environmental applications of the technology. A gene drive forces a genetic modification to spread through an entire population over successive generations, far faster than normal inheritance would allow. For malaria, which kills hundreds of thousands of people annually, two strategies are being developed: suppressing mosquito populations entirely, or modifying mosquitoes so they can no longer carry the malaria parasite.
Lab experiments have shown that a CRISPR gene drive targeting a gene called doublesex caused complete population collapse in caged colonies of Anopheles gambiae, the primary malaria-transmitting mosquito in Africa. More recently, researchers in Tanzania tested gene-drive-capable mosquitoes that carry antiparasitic genes, showing these modified mosquitoes could suppress patient-derived malaria parasites. This work marks an important step because it moved research from labs in Europe and North America to the African countries where malaria is endemic, though field releases have not yet occurred.
Boosting Biofuel Production
Microalgae are promising sources of biofuel because they produce oils (lipids) as they grow, but natural strains don’t produce enough to be commercially competitive. CRISPR has been used to edit algae genomes to dramatically increase their lipid output. In one species, knocking out a single enzyme boosted lipid productivity by about 64%. In another, a double knockout of two genes increased oil productivity by 81% while preserving the algae’s ability to produce valuable pigments. Editing a regulatory gene in a different species doubled lipid production from roughly 2.5 to 5.0 grams per square meter per day, and the modified strain still grew and captured CO2 at rates comparable to the unmodified version.
These aren’t commercial products yet, but they demonstrate CRISPR’s utility in industrial biotechnology, where even modest percentage gains in output can determine whether a process is economically viable.
How CRISPR Gets Into Cells
One practical challenge across all these applications is delivery: getting the CRISPR machinery into the right cells. Two main approaches exist. Viral vectors, essentially hollowed-out viruses, are highly efficient at delivering CRISPR into cells but carry risks. Some types can insert their DNA randomly into the genome, and others can trigger immune reactions.
Non-viral alternatives are gaining ground. Lipid nanoparticles, tiny fat-based capsules similar to those used in mRNA vaccines, have shown strong editing efficiency in the liver and lungs with lower immune toxicity. Biodegradable versions of these nanoparticles have demonstrated durable gene editing lasting at least 12 months in animal studies. Other creative approaches include gold nanoparticles, which achieved efficient gene correction with minimal off-target effects, and extracellular vesicles derived from red blood cells, which showed high editing efficiency with no observed toxicity. The choice of delivery method shapes which organs can be targeted and how safe the therapy is, making it one of the most active areas of development across CRISPR applications.